471 related articles for article (PubMed ID: 23772560)
1. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
[TBL] [Abstract][Full Text] [Related]
2. The ipilimumab lesson in melanoma: achieving long-term survival.
Delyon J; Maio M; Lebbé C
Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
4. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
5. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
6. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Ascierto PA
Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
[TBL] [Abstract][Full Text] [Related]
8. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
Wolchok JD; Weber JS; Maio M; Neyns B; Harmankaya K; Chin K; Cykowski L; de Pril V; Humphrey R; Lebbé C
Ann Oncol; 2013 Aug; 24(8):2174-80. PubMed ID: 23666915
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Lipson EJ; Drake CG
Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
[TBL] [Abstract][Full Text] [Related]
11. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
12. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
Maio M; Di Giacomo AM; Robert C; Eggermont AM
Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Letendre P; Monga V; Milhem M; Zakharia Y
Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab for advanced melanoma: a pharmacologic perspective.
Trinh VA; Hagen B
J Oncol Pharm Pract; 2013 Sep; 19(3):195-201. PubMed ID: 23047236
[TBL] [Abstract][Full Text] [Related]
17. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
Lebbé C; Weber JS; Maio M; Neyns B; Harmankaya K; Hamid O; O'Day SJ; Konto C; Cykowski L; McHenry MB; Wolchok JD
Ann Oncol; 2014 Nov; 25(11):2277-2284. PubMed ID: 25210016
[TBL] [Abstract][Full Text] [Related]
18. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
20. An immune-active tumor microenvironment favors clinical response to ipilimumab.
Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
